5Am Partners Vi, Llc Sells 500,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVNGet Free Report) major shareholder 5Am Partners Vi, Llc sold 500,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.00, for a total value of $7,500,000.00. Following the completion of the sale, the insider now owns 771,983 shares of the company’s stock, valued at $11,579,745. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Enliven Therapeutics Trading Down 6.3 %

Shares of ELVN stock opened at $15.41 on Monday. The stock has a market cap of $635.05 million, a P/E ratio of 4.82 and a beta of 1.06. The stock has a 50 day simple moving average of $13.23 and a 200 day simple moving average of $14.15. Enliven Therapeutics, Inc. has a 1 year low of $9.80 and a 1 year high of $25.34.

Enliven Therapeutics (NASDAQ:ELVNGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). Analysts forecast that Enliven Therapeutics, Inc. will post -2.24 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently made changes to their positions in ELVN. Metropolitan Life Insurance Co NY bought a new stake in shares of Enliven Therapeutics in the second quarter valued at approximately $26,000. Tower Research Capital LLC TRC bought a new stake in Enliven Therapeutics during the first quarter worth $36,000. Ameritas Investment Partners Inc. bought a new stake in Enliven Therapeutics during the second quarter worth $39,000. Royal Bank of Canada lifted its stake in Enliven Therapeutics by 532.7% during the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock worth $63,000 after purchasing an additional 2,589 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Enliven Therapeutics during the fourth quarter worth $66,000. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

See Also

Insider Buying and Selling by Quarter for Enliven Therapeutics (NASDAQ:ELVN)

Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.